SM
Sabby Management Portfolio holdings
AUM
$13M
This Quarter Return
+3.7%
1 Year Return
-26.95%
3 Year Return
-56.43%
5 Year Return
-61.92%
10 Year Return
-71.17%
AUM
$77M
AUM Growth
+$77M
(+167%)
Cap. Flow
+$44.1M
Cap. Flow
% of AUM
57.26%
Top 10 Holdings %
Top 10 Hldgs %
76.76%
Holding
105
New
31
Increased
5
Reduced
14
Closed
38
Top Buys
| 1 |
Biogen
BIIB
|
$27.8M |
| 2 |
Health Care Select Sector SPDR Fund
XLV
|
$7.09M |
| 3 |
Moderna
MRNA
|
$4.62M |
| 4 |
Xeris Biopharma Holdings
XERS
|
$2.89M |
| 5 |
PLLL
Piedmont Lithium Limited American Depositary Receipts
PLLL
|
$2.88M |
Top Sells
| 1 |
SPDR Gold Trust
GLD
|
$2.66M |
| 2 |
Enlivex Therapeutics
ENLV
|
$2.18M |
| 3 |
NOVN
Novan, Inc. Common Stock
NOVN
|
$2.11M |
| 4 |
Outlook Therapeutics
OTLK
|
$1.94M |
| 5 |
Pluri
PLUR
|
$1.44M |
Sector Composition
| 1 | Healthcare | 73.93% |
| 2 | Industrials | 1.66% |
| 3 | Consumer Discretionary | 0.57% |
| 4 | Financials | 0.41% |
| 5 | Consumer Staples | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Aurinia Pharmaceuticals
AUPH
$1.58B
| $406K | 0.08% |
25,000
-17,500
| -41% | -$284K |
|
27
Genprex
GNPX
$5.49M
| $372K | 0.07% |
+118,584
| New | +$372K |
|
28
Predictive Oncology
POAI
$9.8M
| $367K | 0.07% |
+223,540
| New | +$367K |
|
|
PHAS
29
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $354K | 0.07% |
76,970
-30,607
| -28% | -$141K |
|
30
Actinium Pharmaceuticals
ATNM
$53.3M
| $342K | 0.07% |
972,285
+350,445
| +56% | +$123K |
|
|
GNCA
31
DELISTED
Genocea Biosciences, Inc.
GNCA
| $288K | 0.06% |
125,312
-314,962
| -72% | -$724K |
|
32
Dominari Holdings
DOMH
$86.7M
| $281K | 0.06% |
+342,121
| New | +$281K |
|
|
33
Pluri
PLUR
$40.5M
| $263K | 0.05% |
29,699
-162,350
| -85% | -$1.44M |
|
34
SPDR S&P Biotech ETF
XBI
$5.29B
| $241K | 0.05% |
+2,150
| New | +$241K |
|
|
BPTH
35
DELISTED
Bio-Path Holdings Inc
BPTH
| $227K | 0.05% |
45,000
-109,290
| -71% | -$551K |
|
36
Arcadia Biosciences
RKDA
$4.27M
| $224K | 0.05% |
+59,543
| New | +$224K |
|
37
Hoth Therapeutics
HOTH
$17.6M
| $177K | 0.04% |
+68,681
| New | +$177K |
|
|
MDGSW
38
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
| $123K | 0.02% |
585,859
-421,585
| -42% | -$88.5K |
|
39
Benitec Biopharma
BNTC
$365M
| $94K | 0.02% |
11,863
-9,729
| -45% | -$20.1K |
|
40
Palisade Bio
PALI
$6.04M
| $83K | 0.02% |
115,001
-310
| -0.3% | – |
|
|
MARK
41
DELISTED
Remark Holdings, Inc.
MARK
| $80K | 0.02% |
+33,953
| New | +$80K |
|
|
RDGT
42
Ridgetech, Inc. Ordinary Shares
RDGT
$6.79M
| $69K | 0.01% |
+50,000
| New | +$69K |
|
|
43
Enlivex Therapeutics
ENLV
$25.3M
| $65K | 0.01% |
12,925
-432,748
| -97% | -$2.18M |
|
44
Inovio Pharmaceuticals
INO
$144M
| $54K | 0.01% |
+2,000
| New | +$54K |
|
|
TEUM
45
DELISTED
Pareteum Corporation
TEUM
| $35K | 0.01% |
56,757
-515,514
| -90% | -$318K |
|
46
LM Funding America
LMFA
$16.7M
| $34K | 0.01% |
+25,000
| New | +$34K |
|
47
ReWalk Robotics
LFWD
$8.96M
| $34K | 0.01% |
19,082
-210,617
| -92% | -$375K |
|
48
InspireMD
NSPR
$101M
| $22K | ﹤0.01% |
48,300
+37,264
| +338% | +$17K |
|
49
Pulmatrix
PULM
$17M
| $21K | ﹤0.01% |
+11,944
| New | +$21K |
|
50
Lipocine
LPCN
$15.7M
| $18K | ﹤0.01% |
+14,452
| New | +$18K |
|